Wegovy vs Saxenda: Which works better, and why

Wegovy and Saxenda look almost identical on the shelf.

Both are pre-filled pens, both come from Novo Nordisk, and both are licensed in the UK for weight management.

So when the trial evidence puts one so far ahead of the other, it is reasonable to wonder what you are missing.

You are not missing anything. The two treatments really are that different in effect.

What follows is not an argument for one over the other.

It puts both medicines on the scale across the seven things that separate them:

• How much weight loss each produces
• How often you have to inject
• How the side effects arrive
• How many people stay the course
• What else each is licensed to treat
• How long each has been in use
• How easily you can get hold of one

On the question of who should not take either, they are near-identical, and we cover that as well.

One thing to be upfront about: OnlineClinic prescribes Wegovy, not Saxenda or liraglutide.

We have still written the Saxenda side straight, including the part where liraglutide is the better answer, because a half-answer would not be worth reading.

If GLP-1 medications are new to you entirely, our complete UK guide to GLP-1 medications covers the groundwork first.

Before you begin: A little bit about OnlineClinic

OnlineClinic has been operating since 2011 and has treated more than 2.1 million patients.

The pharmacy is registered with the General Pharmaceutical Council (GPhC), our prescribers are registered with the General Medical Council (GMC), and the service is regulated by the Care Quality Commission (CQC).

As of August 2026, on Trustpilot, the service rating is 4.6 out of 5 based on 6,491 reviews.

Here is everything that has moved, in one place.

• Wegovy's dose ceiling went up.

The MHRA approved a 7.2mg maximum weekly dose in January 2026, and a single-injection 7.2mg pen in April 2026.

The old ceiling was 2.4mg, so most older comparisons are measuring a weaker version of Wegovy than the one available now.

• Wegovy is licensed to cut cardiovascular risk.

Since July 2024, it has held a UK licence for reducing the risk of heart attack and stroke in adults with established cardiovascular disease and a BMI of 27 or above, and NICE recommended it for that use in April 2026.

It is the first and only GLP-1 medication with a NICE recommendation for this purpose. Saxenda has no equivalent licence.

We cover the evidence in detail in Wegovy and heart disease.

• Wegovy has a conditional licence for liver disease.

In June 2026, the MHRA approved Wegovy for metabolic-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis.

Two caveats matter.

It is a conditional authorisation, granted on the condition that further study results are submitted, because more evidence on how well it works for MASH is still needed before a full licence can be issued.

And treating MASH is a specialist decision rather than something you can access through a weight-management consultation, so it is not yet a route for most people with the condition.

• Semaglutide now comes as a tablet.

On 11 June 2026, the MHRA approved oral semaglutide for weight management, the first GLP-1 tablet licensed for this in the UK.

It contains the same medicine as the injection, taken once daily, escalating from 1.5mg to 4mg to 9mg to 25mg, with at least a month at each step.

The catch is the routine: The pill needs to be swallowed whole on an empty stomach after fasting at least eight hours, with no more than a sip of water, and nothing to eat or drink for 30 minutes afterwards.

Miss that window and absorption drops. Our guide to the oral semaglutide tablet covers who it suits.

• The Saxenda brand has been hard to get, but liraglutide has not gone away.

Saxenda has been in restricted UK supply for some time.

Liraglutide itself remains licensed for weight management and is now available in generic form under other brand names, with the same active ingredient in different packaging at a different price.

So the real question is often less "Saxenda or Wegovy" and more "liraglutide or semaglutide", which is how we have framed the evidence below.

Both medicines mimic a gut hormone called GLP-1.

Your body releases it after you eat, and it does three useful things: It tells your brain you have had enough, slows how fast your stomach empties, and reduces food cravings.

Semaglutide and liraglutide switch on the same receptor in the body. What differs is how long they last in the body, and that difference is the biggest factor to consider when making a choice.

Liraglutide is chemically very close to the natural hormone, so the body clears it at close to natural speed.

Its half-life is roughly 13 hours, which is why it has to be injected every day.

Semaglutide has been modified to resist that breakdown, and it binds to a blood protein that carries it around slowly.

Its half-life is about a week, so one injection covers seven days.

A once-weekly medicine sits at a steady level in the blood rather than rising and falling each day, and steadier levels are better tolerated.

That is why semaglutide can be escalated to a much higher effective dose without becoming intolerable, while liraglutide reaches its tolerability limit at 3.0mg a day and stops there.

More sustained appetite signalling at a higher dose produces more weight loss as well. The head-to-head trial below explains this in detail.

Most weight loss comparisons stitch separate trials together. But this one is an exception.

The STEP 8 trial ran 68 weeks and enrolled 338 non-diabetic participants with a BMI of 30 or above, or 27 or above with a weight-related condition. They were given either Wegovy on a weekly basis or Saxenda on a daily basis along with a balanced diet and adequate exercise.

Average weight loss achieved at 68 weeks:

70.9% of participants and 25.6% of participants lost at least 10% body weight on Wegovy and Saxenda, respectively.

55.6% of participants and 12.0% of participants lost at least 15% body weight on Wegovy and Saxenda, respectively.

38.5% of participants and 6.0% of participants lost at least 20% body weight on Wegovy and Saxenda, respectively.

One caveat. The STEP 8 tested Wegovy at 2.4mg, because that was Wegovy’s highest dose at that time.

Wegovy now goes to 7.2mg, which produced more weight loss again in its own trial, so the measured gap is the conservative version.

A second and more important caveat. These are averages across hundreds of people.

Some people on Saxenda lose more than the Wegovy average, and some people on Wegovy lose very little.

Nobody, including your prescriber, can tell you in advance which medicine will make you lose more weight.

The head-to-head result is quite important. But, the individual clinical trials for each medicine will guide you further.

Saxenda at 3.0mg (SCALE). Published in the New England Journal of Medicine in 2015, this trial followed 3,731 adults for 56 weeks. Average weight loss was 8.0% on Saxenda against 2.6% on placebo. Around 63% of participants lost at least 5% of their starting weight, and about 33% of participants lost at least 10% of their starting weight.

Wegovy at 2.4mg (STEP 1). Published in the same journal in 2021, following 1,961 adults for 68 weeks. Average weight loss was 14.9% against 2.4% on placebo.

Wegovy at 7.2mg (STEP UP). Published in The Lancet Diabetes & Endocrinology in 2025, testing the higher dose in 1,407 adults over 72 weeks. Average weight loss was 18.7% on the 7.2mg dose, against 15.6% at 2.4mg dose, and 3.9% on placebo.

It might sound like a small thing, but the frequency of a weight loss injection plays a huge role in determining whether users continue with their treatment in the long run.

Neither Wegovy nor Saxenda is difficult to use. Both injection pens use very short needles, and you might find the injection far less unpleasant than you imagined.

The difference is cumulative, though: roughly 52 injections a year for Wegovy against roughly 365 injections a year for Saxenda.

A weekly injection might feel like a small Sunday-evening habit that fades into the background within a month.

A daily injection feels like a ritual to remember before bed every night, something to pack for a weekend away, a daily reminder that you are on treatment.

This shows up in the trial data too.

In the STEP 8 trial, 27.6% of participants using Saxenda stopped treatment for one reason or another, against 13.5% of participants on Wegovy.

Twice as many people walked away from the daily injection.

Because Wegovy and Saxenda work in similar ways, the side effects they produce are quite similar too.

In the STEP 8 trial, gastrointestinal side effects affected 84.1% of participants using Wegovy and 82.7% of participants using Saxenda.

The most common effects for both treatments are:

• Nausea, usually worst in the first couple of weeks after the dose
• Constipation and diarrhoea
• Vomiting
• Reduced appetite, which is partly the intended effect, but it can feel strange at first
• Tiredness and headache

Saxenda climbs to its full 3.0mg dose in 0.6mg steps at weekly intervals, reaching the highest dose in about five weeks, so the body’s adjustment period is short and steep.

Wegovy climbs over roughly 16 to 20 weeks, spreading it much thinner. Many users find the gradual version easier, which is why fewer users discontinue their Wegovy treatment as compared to Saxenda treatment.

We cover the timeline in Wegovy side effects week by week, and the full dose ladder in Wegovy dosage schedule explained.

When to stop and get medical help

Both treatments carry the same rare but serious risks. These are worth recognising rather than worrying about.

Call 999 or go to your nearest emergency department if you have:

• Severe stomach pain that does not settle, often spreading through to your back, sometimes with vomiting. This can be pancreatitis, inflammation of the pancreas. Stop the injection and get seen urgently.
• Swelling of the face, lips, tongue, or throat, difficulty breathing, or a widespread rash. This can be a serious allergic reaction.

Contact a doctor the same day if you have:

• Pain under your right ribs, yellowing of the skin or eyes, or pale stools. Rapid weight loss of any kind can trigger gallstones.
• Signs of low blood sugar, such as shaking, sweating, or confusion. This is more likely if you also take insulin or a sulphonylurea.

Suspected side effects can also be reported through the MHRA Yellow Card scheme.

There is still one area where Saxenda genuinely leads, and there are three situations where it is the more sensible choice.

• The longest real-world record. Liraglutide, the active ingredient in Saxenda, has been licensed for weight management in the UK since 2015, six years ahead of semaglutide, and the same molecule has been in clinical use for type 2 diabetes since 2009.

Where a medical history is complicated, some prescribers may rely on the medicine’s extensive real-world record.

• You already know it suits you. If you have taken Saxenda, tolerated it, and lost weight on it, that is direct evidence about your own body, and it outranks any trial average.
• A finer climb to full dose. The Saxenda dose rises in 0.6mg steps with at least a week between them, and an increase can be delayed if a dose doesn’t feel right.

One limit worth knowing: The licence directs prescribers to consider stopping if a step is still not tolerated after two consecutive weeks, because Saxenda has not been shown to work well below 3.0mg. The flexibility is in the pace of the climb, not in settling at a lower dose.

There is no universally right answer, but the decision usually relies on a few practical points.

• Wegovy tends to be an ideal choice if maximum average weight loss is the priority, a weekly injection suits your life better than a daily one, or you have established cardiovascular disease and a BMI of 27 or above.
• Saxenda tends to be an ideal choice if you have taken it before and got on with it, you or your prescriber trust its longer real-world record, or it is the only option actually available to you.
• Either may be an appropriate choice if you are starting weight loss injections for the first time with no strong preference, and a prescriber is content with both options after reviewing your history.

If you are also considering starting Mounjaro, our Mounjaro vs Wegovy comparison covers that decision, and Mounjaro vs Ozempic explains why Ozempic is not a UK weight loss option at all.

The UK product information for both treatments lists one outright contraindication: A known hypersensitivity to the active ingredient or to any of the other ingredients in the medicine.

Neither should be used in pregnancy or while breastfeeding, and you should stop and speak to a prescriber if you become pregnant.

Beyond that, the decision is a clinical judgement rather than a fixed list. Tell your prescriber if you have:

• A history of pancreatitis or gallbladder disease
• Severe kidney or liver problems
• Diabetic retinopathy, particularly if you use insulin
• A history of an eating disorder
• Any personal or family history of thyroid cancer or thyroid disease
• Other diabetes medication, especially insulin or a sulphonylurea
• Severe gastrointestinal problems such as gastroparesis

Eligibility also requires a BMI of 30 or above, or 27 or above with at least one weight-related condition (type 2 diabetes, high blood pressure, sleep apnoea, fatty liver disease, PCOS, osteoarthritis, or heart disease).

If neither applies to you, GLP-1 treatment is not the right route for you, and our prescribers will explain what might help instead.

Our Wegovy prices start from £69.99 for the starter dose, and higher doses cost more.

Every price includes the prescription, the consultation, the packaging, and next-day delivery.

There are no hidden fees, and you are not charged for treatment that is not issued.

Wegovy also has a subscription option with savings on repeat deliveries, which you can pause, skip, or cancel at any time from your account.

We do not prescribe Saxenda or generic liraglutide, so we cannot quote you a price for it.

If Saxenda is what you and a prescriber decide you want, you will need a service that dispenses it.

At OnlineClinic, from start to finish, the entire process is quite straightforward.

1. Fill in a short medical questionnaire. It takes 5 to 10 minutes and covers your medical history, current medications, height, and weight, and any allergies. The questions are thorough on purpose because the prescriber uses them to check if the treatment is safe for you.
2. A GMC-registered prescriber reviews your answers. If they need more detail, they message you through your account. No phone tag and no appointment to attend.
3. If treatment is approved, it is dispensed and dispatched. Next-day delivery, with everything you need included (needles, sharps bin, and the patient information leaflet). Wegovy pens are stable below 30°C and ship in standard insulated packaging, so no ice pack is needed.
4. If treatment is not approved, the prescriber explains why. They may suggest an alternative, and you are not charged for treatment that is not issued.

Our pharmacy is registered with the GPhC, our prescribers with the GMC, and the service is regulated by the CQC. Those registers are public, so you can check us before you order.